Picture loading failed.

Anti-NGFB therapeutic antibody (Pre-made Tanezumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-549-1mg 1mg 3090
GMP-Bios-ab-549-10mg 10mg 21890
GMP-Bios-ab-549-100mg 100mg 148000
GMP-Bios-ab-549-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-NGFB therapeutic antibody (Pre-made Tanezumab biosimilar,Whole mAb)
INN Name Tanezumab
TargetNGFB
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI Structure4edw:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesRinat Neuroscience;Pfizer
Conditions Approvedna
Conditions ActiveBack pain;Cancer pain;Musculoskeletal pain
Conditions DiscontinuedDiabetic neuropathies;Postherpetic neuralgia
Development Techna